Prognostic and predictive markers in medullary thyroid carcinoma (Q43891433)

27 November 2017

title

Prognostic and predictive markers in medullary thyroid carcinoma (English)

1 reference

27 November 2017

1 reference

27 November 2017

Boban M Erovic

0 references

Ozgur Mete

0 references

David P Goldstein

1 reference

27 November 2017

Jonathan C Irish

1 reference

27 November 2017

Dae Kim

1 reference

27 November 2017

Clarissa Cassol

series ordinal

1 reference

27 November 2017

language of work or name

1 reference

1 December 2012

1 reference

27 November 2017

1 reference

27 November 2017

1 reference

27 November 2017

1 reference

27 November 2017

page(s)

232-242

1 reference

Evidence-based approach to the management of sporadic medullary thyroid carcinoma

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution's experience over 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Radioactive iodine treatment in medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Current approaches to medullary thyroid carcinoma, sporadic and familial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Medullary thyroid carcinoma and biomarkers: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

New therapeutic approaches to treat medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Medullary thyroid cancer: therapeutic targets and molecular markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

The RET proto-oncogene: a molecular therapeutic target in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

The RET proto-oncogene: a potential target for molecular cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Phase II trial of sorafenib in advanced thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Rap1 stabilizes beta-catenin and enhances beta-catenin-dependent transcription and invasion in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Apoptosis and cancer: the genesis of a research field

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

GSTpi modulates JNK activity through a direct interaction with JNK substrate, ATF2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Co-expression of Bmi-1 and podoplanin predicts overall survival in patients with squamous cell carcinoma of the head and neck treated with radio(chemo)therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Expression of BMI-1 in normal skin and inflammatory and neoplastic skin lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Antisense RNA-mediated suppression of Bmi-1 gene expression inhibits the proliferation of lung cancer cell line A549.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Radionuclide therapy in neuroendocrine tumours: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Pancreatic endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9225-8

Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.

21 January 2018

1 reference

12 December 2020

Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen

1 reference

12 December 2020

Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.

1 reference

12 December 2020

Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies

1 reference

12 December 2020

BAY 43-9006 inhibition of oncogenic RET mutants

1 reference

12 December 2020

Expression of hedgehog signaling molecules in Merkel cell carcinoma.

1 reference

12 December 2020

WNT signaling pathway and stem cell signaling network

1 reference

12 December 2020

Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease

1 reference

12 December 2020

Novel cytotoxic agents for non-small cell lung cancer

1 reference

12 December 2020

10.1007/S12022-012-9225-8

Identifiers

DOI

1 reference

Dimensions Publication ID

27 November 2017

1018162282

0 references

1 reference